In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 351 to 360 of 379

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6406]	Technology appraisal guidance	2 December 2026
Tovorafenib for treating relapsed or refractory paediatric low-grade glioma with BRAF fusion or rearrangement or BRAF V600 mutation in people 6 months and over [ID6557]	Technology appraisal guidance	TBC
Transvaginal radiofrequency ablation for symptomatic uterine fibroids	HealthTech guidance	TBC
Trastuzumab deruxtecan for treating HER2-positive advanced gastric or gastro-oesophageal junction adenocarcinoma after trastuzumab-based treatment (review of TA879) [ID6680]	Technology appraisal guidance	13 January 2027
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 therapies (MA review TA704 and TA862) [ID5121]	Technology appraisal guidance	TBC
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309]	Technology appraisal guidance	TBC
Trilaciclib for preventing myelosuppression caused by chemotherapy for extensive-stage small-cell lung cancer [ID6651]	Technology appraisal guidance	TBC
Unilateral MRI-guided focused ultrasound thalamotomy for medication-refractory essential tremor	HealthTech guidance	17 December 2026
Upadacitinib for treating giant cell arteritis [ID6299]	Technology appraisal guidance	14 October 2026
Vamikibart for treating uveitic macular oedema ID6671	Technology appraisal guidance	TBC

Results per page

10
25
50
All